USA UH  2022 ED & Freestanding ED Antibiogram  % Susceptible All culture types	TOTAL ISOLATES	Amikacin <sup>a,b</sup>	Ampicillin	Ampicillin-sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Clindamycin	Daptomycin	Ertapenem	Gentamicin <sup>a,c</sup>	Levofloxacin	Linezolid	Meropenem	Nitrofurantoin	Oxacillin	Penicillin	Piperacillin-tazobactam	Tetracycline	<b>Tobramycin</b> <sup>a</sup>	Trimethoprim-sulfamethoxazole	Vancomycin
Enterococcus faecalis	52		100								98			89	98		100		100		25			100
Escherichia coli	649	100	45	50	92	78	94	91	91			99	88	83		99	98			97	76	87	69	
Klebsiella pneumoniae	166	100	0	67	86	74	86	85	85			96	92	93		99	51			86	72	90	81	
Proteus mirabilis	48	100	77	85	100	29	98	98	90			96	96	88			0			100	0	94	85	
Pseudomonas aeruginosa	46	100			85		96	91					96	76		85				85		98		
Staphylococcus aureus	68									84	100		98	77	100		100	59			93		94	100

<sup>a</sup>Gentamicin, tobramycin, and amikacin should only be used in combination when treating Gram-negative infections.

- The numbers displayed above represent the percentage of organisms susceptible to the specified antibiotic.
- Antibiogram data helps guide clinicians to choose appropriate empiric antibiotics for infectious syndromes before susceptibility is available. Once susceptibility is known, tailor to most narrow-spectrum agent for the patient's specific organism.
- Blank cells indicate drug not tested or usually not indicated.
- 30 isolate threshold
- Clinical practice guidelines generally recommend selecting antibiotics with >80% susceptibility for the known pathogen or most likely pathogens.

<sup>&</sup>lt;sup>b</sup>Amikacin anti-Pseudomonal activity is applicable to urine cultures only.

<sup>&</sup>lt;sup>c</sup>Gentamicin should only be used in combination when treating Gram-positive infections.